OncoSil Medical Limited (OSL.AX)
- Previous Close
0.0050 - Open
0.0050 - Bid 0.0050 x 64817800
- Ask 0.0060 x 53786700
- Day's Range
0.0050 - 0.0050 - 52 Week Range
0.0040 - 0.0130 - Volume
554,320 - Avg. Volume
4,575,472 - Market Cap (intraday)
16.661M - Beta (5Y Monthly) 0.42
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date Aug 29, 2024 - Sep 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.
www.oncosil.com.auRecent News: OSL.AX
Performance Overview: OSL.AX
Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OSL.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OSL.AX
Valuation Measures
Market Cap
16.66M
Enterprise Value
11.88M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
33.34
Price/Book (mrq)
4.08
Enterprise Value/Revenue
49.63
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-103.64%
Return on Equity (ttm)
-237.87%
Revenue (ttm)
1.3M
Net Income Avi to Common (ttm)
-11.71M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
4.89M
Total Debt/Equity (mrq)
2.62%
Levered Free Cash Flow (ttm)
-5.93M